NCT04884035 2026-02-04Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaCelgenePhase 1 Recruiting174 enrolled
NCT04882163 2021-10-05Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaCelgenePhase 1/2 Withdrawn